Takeda july FY25
Ended Awarded Last action
- Contract number
- 15B50925F00000223
- Awardee
-
Takeda Pharmaceuticals America, Inc. UEI DDEVYUAXJ624
- Awarding agency
-
Federal Correctional Institution Fort Worth
Correctional Facilities, Department of Justice
- Obligated
- $102,404
Award facts
- Contract value 100% obligated
- $102,404.25 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Lexington, MA 02421, USA
Award details come from SAM.gov/FPDS.
About this award
Takeda Pharmaceuticals America Inc., a subsidiary of Japan-based Takeda Pharmaceutical Company Limited, was awarded a delivery order valued at $102,404.25 by the Federal Correctional Institution Fort Worth on July 1, 2025, with an ultimate completion date of July 31, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a child award under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB). The contract calls for delivery of specialized pharmaceutical products to the place of performance in Lexington, Massachusetts. Takeda Pharmaceuticals America Inc. specializes in manufacturing advanced pharmaceutical treatments across multiple therapeutic areas, including rare diseases, hematology, immunology, and oncology, serving federal healthcare systems through the Bureau of Prisons and other government agencies.
This award is part of Takeda's broader engagement with federal healthcare procurement, supported by a significant Blanket Purchase Agreement with the VA National Acquisition Center valued at $131,039,520.00 running through July 14, 2026. The company's federal contract portfolio demonstrates consistent focus on delivering critical medications including CINRYZE, ADVATE, GAMMAGARD, TAKHZYRO, LIVTENCITY, FEIBA, and OBIZUR to support patient care programs across the Department of Veterans Affairs, Department of Justice Bureau of Prisons, and Department of Defense. The specialized nature of these pharmaceutical products and their limited supplier base explains the absence of set-aside utilization across Takeda's federal contracts.
Quick answers
Who was awarded contract 15B50925F00000223?
15B50925F00000223 was awarded to Takeda Pharmaceuticals America, Inc. by Federal Correctional Institution Fort Worth (Correctional Facilities) on July 1, 2025.
How much is contract 15B50925F00000223 worth?
The government has obligated $102,404 on 15B50925F00000223.
Is contract 15B50925F00000223 an order under another contract?
Yes. 15B50925F00000223 is a delivery order under V797D50492, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 15B50925F00000223 competed?
The extent of competition for 15B50925F00000223 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award